Health care stocks were advancing pre-bell Thursday as the iShares Biotechnology ETF (IBB) was marginally higher and the Health Care Select Sector SPDR Fund (XLV) was up 0.1% recently.
ClearPoint Neuro (CLPT) shares were up nearly 10% after the company said the US Food and Drug Administration has granted De Novo marketing authorization for its SmartFlow Neuro Cannula for the delivery of PTC Therapeutics' Kebilidi gene therapy to targeted regions within the brain.
PTC Therapeutics (PTCT) shares were over 2% higher after the company said the US Food and Drug Administration has accelerated approval of Kebilidi, the company's gene therapy for aromatic L-amino acid decarboxylase deficiency.
BeiGene (BGNE) shares were 0.8% higher after the company said it plans to change its name to BeOne Medicines, subject to shareholder approval.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。